ADAMTS13 and von willebrand factor concentrations in patients with diabetes mellitus

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 8, 2009, Pages 619-626

  Skeppholm, Mika ^a   Kallner, Anders ^c   Kalani, Majid ^a   Jörneskog, Gun ^b   Blombäck, Margareta ^c   Wallén, Håkan N ^a  

^a DANDERYD HOSPITAL   (Sweden)

^b Internal Medicine   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

ADAMTS13; Age; Dalteparin; Diabetes mellitus; Inflammation; Low molecular weight heparin; Peripheral artery occlusive disease; Sex; Von Willebrand factor

Indexed keywords

ANTIGEN; DALTEPARIN; PLACEBO; VON WILLEBRAND FACTOR; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC MICROANGIOPATHY; FEMALE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLASMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL; TREATMENT RESPONSE;

ADAM PROTEINS; ADULT; AGED; AGED, 80 AND OVER; ARTERIAL OCCLUSIVE DISEASES; CASE-CONTROL STUDIES; DALTEPARIN; DIABETES COMPLICATIONS; DIABETES MELLITUS; FEMALE; HUMANS; MALE; MIDDLE AGED; VON WILLEBRAND FACTOR;

EID: 70449570950     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832da183     Document Type: Article

References (20)

1. Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem 1998; 67:395-424.
2. Shim K, Anderson PJ, Tuley EA, Wiswall E, Sadler JE. Platelet-VWF complexes are preferred substrates of ADAMTS13 under fluid shear stress. Blood 2008; 111:651-657.
3. Blomback B. A journey with bleeding time factor. Compr Biochem 2007; 45:209-255.
4. Moake JL. Thrombotic microangiopathies. N Engl J Med 2002; 347:589-600.
5. Hovinga JA, Studt JD, Alberio L, Lammle B. von Willebrand factor-cleaving protease (ADAMTS-13) activity determination in the diagnosis of thrombotic microangiopathies: the Swiss experience. Semin Hematol 2004; 41:75-82.
6. Stehouwer CD, Fischer HR, Van Kuijk AW, Polak BC, Donker AJ. Endothelial dysfunction precedes development of microalbuminuria in IDDM. Diabetes 1995; 44:561-564.
7. Stehouwer CD, Nauta JJ, Zeldenrust GC, Hackeng WH, Donker AJ, Den Ottolander GJ. Urinary albumin excretion, cardiovascular disease, and endothelial dysfunction in noninsulin-dependent diabetes mellitus. Lancet 1992; 340:319-323.
8. Stehouwer CD, Gall MA, Twisk JW, Knudsen E, Emeis JJ, Parving HH. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. Diabetes 2002; 51:1157-1165.
9. Standl E, Balletshofer B, Dahl B, Weichenhain B, Stiegler H, Hormann A, et al. Predictors of 10-year macrovascular and overall mortality in patients with NIDDM: the Munich General Practitioner Project. Diabetologia 1996; 39:1540-1545.
10. Van Mourik JA, Boertjes R, Huisveld IA, Fijnvandraat K, Pajkrt D, Van Genderen PJ, et al. von Willebrand factor propeptide in vascular disorders: a tool to distinguish between acute and chronic endothelial cell perturbation. Blood 1999; 94:179-185.
11. Silveira AM, Sjoberg S, Blomback M, Ostman J. von Willebrand factor antigen in plasma and urine in patients with type I (insulin-dependent) diabetes mellitus with and without nephropathy. J Diabet Complic 1992; 6:89-95.
12. Kokame K, Nobe Y, Kokubo Y, Okayama A, Miyata T. FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay. Br J Haematol 2005; 129:93-100.
13. Kalani M, Apelqvist J, Blomback M, Brismar K, Eliasson B, Eriksson JW, et al. Effect of dalteparin on healing of chronic foot ulcers in diabetic patients with peripheral arterial occlusive disease: a prospective, randomized, doubleblind, placebo-controlled study. Diabetes Care 2003; 26:2575-2580.
14. Kalani M, Silveira A, Blomback M, Apelqvist J, Eliasson B, Eriksson JW, et al. Beneficial effects of dalteparin on haemostatic function and local tissue oxygenation in patients with diabetes, severe vascular disease and foot ulcers. Thromb Res 2007; 120:653-661.
15. Oldgren J, Fellenius C, Boman K, Jansson JH, Nilsson TK, Wallentin L, et al. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease. J Intern Med 2005; 258:420-427.
16. Vischer UM. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4:1186-1193.
17. Kaikita K, Soejima K, Matsukawa M, Nakagaki T, Ogawa H. Reduced von Willebrand factor-cleaving protease (ADAMTS13) activity in acute myocardial infarction. J Thromb Haemost 2006; 4:2490-2493.
18. Montalescot G, Philippe F, Ankri A, Vicaut E, Bearez E, Poulard JE, et al. Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998; 98:294-299.
19. Mannucci PM, Canciani MT, Forza I, Lussana F, Lattuada A, Rossi E. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood 2001; 98:2730-2735.
20. Nishio K, Anderson PJ, Zheng XL, Sadler JE. Binding of platelet glycoprotein Ibalpha to von Willebrand factor domain A1 stimulates the cleavage of the adjacent domain A2 by ADAMTS13. Proc Natl Acad Sci U S A 2004; 101:10578-10583.